hai mortality—mdr gram-negative bacteria and mrsa 855
the VA, we identified a significant and substantial increase in mortality attributable to HAIs due to 4 different antibiotic- resistant organisms of 4.9% for MDR gram-negative bacteria and 5.9% for MRSA. Important future work will include evaluating interventions to prevent resistant HAIs to deter- mine their effect on mortality.
acknowledgments
The views expressed in this article are those of the authors and do not neces- sarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Financial support: This study was conducted through a contract with
the Centers for Disease Control and Prevention and was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (grant nos. CDA 11-210 and I50HX001240). This report is the result, in part, of work supported with resources and the use of facilities of the George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah. Potential conflicts of interest: All authors report no conflicts of interest
relevant to this article. Address correspondence to Richard E. Nelson, PhD, 500 Foothill Blvd,
Salt Lake City, UT 84148 (
richard.nelson@
utah.edu).
supplementary material To view supplementary material for this article, please visit https:/
doi.org/10.1017/ice.2017.83
references
1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point- prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198–1208.
2. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 2013;34:1–14.
3. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804–1813.
4. Schweizer ML, Eber MR, Laxminarayan R, et al. Validity of ICD-9-CM coding for identifying incident methicillin-resistant Staphylococcus aureus (MRSA) infections: is MRSA infection coded as a chronic disease? Infect Control Hosp Epidemiol 2011;32:148–154.
5. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mor- tality and costs. Infect Control Hosp Epidemiol 2011;32:101–114.
90 days of the index date regardless of patient locations; thereby, we avoided informative censoring. Estimates from analyses that are restricted to the in-hospital period may be biased due to the competing risk of discharge because patients with an HAI are less likely to be discharged and because patients are also at risk of death after leaving the hospital. In conclusion, using clinical and administrative data from
6. Waters TM, Daniels MJ, Bazzoli GJ, et al. Effect of Medicare’s nonpayment for hospital-acquired conditions: lessons for future policy. JAMA Intern Med 2015;175:347–354.
7. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007;26: 793–800.
8. Daniels TL, Deppen S, Arbogast PG, Griffin MR, Schaffner W, Talbot TR. Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in surgical intensive care units. Infect Control Hosp Epidemiol 2008;29:1080–1083.
9. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007;28:293–298.
10. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acine- tobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007;65:204–211.
11. Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug- resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13:97–103.
12. Neily J, Mills PD, Young-Xu Y, et al. Association between implementation of a medical team training program and surgical mortality. JAMA 2010;304:1693–1700.
13. Jones M, DuVall SL, Spuhl J, Samore MH, Nielson C, Rubin M. Identification of methicillin-resistant Staphylococcus aureus within the nation’s Veterans Affairs medical centers using natural language processing. BMC Med Inform Decis Mak 2012;12:34.
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.
15. Branch-Elliman W, Strymish J, Gupta K. Development and validation of a simple and easy-to-employ electronic algorithm for identifying clinical methicillin-resistant Staphylo- coccus aureus infection. Infect Control Hosp Epidemiol 2014; 35:692–698.
16. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749–759.
17. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
18. Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M. Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inform Med 2009;48:438–443.
19. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009;30: 746–752.
20. Ababneh M, Harpe S, Oinonen M, Polk RE. Trends in ami- noglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol 2012;33:594–601.
21. Landman D, Babu E, Shah N, et al. Transmission of carbapenem- resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother 2012;67:1427–1431.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136
